🇫🇷 S3E7 - Le TCA un test, plusieurs objectifs

Bienvenue chez « Ask Stago », le podcast dédié à fournir des réponses d'experts à vos questions d'experts en hémostase.  

Dans notre épisode aujourd’hui notre experte Céline Ayel, nous parlera du test TCA.

Pour en savoir plus :

Littérature :

• Toulon, P., Eloit, Y., Smahi, M., Sigaud, C., Jambou, D., Fischer, F. and Appert‐Flory, A. (2016), In vitro sensitivity of different activated partial thromboplastin time reagents to mild clotting factor deficiencies. Int. Jnl. Lab. Hem., 38: 389-396. https://doi.org/10.1111/ijlh.12499
• CLSI One-stage Prothrombin Time (PT) test and Activated Partial Thromboplastin Time (APTT) test; Approved guideline - second edition. CLSI document H47-A2 Wayne, PA: Clinical and Laboratory Standard Institute, 2008
•   Levy JH, Szlam F, Wolberg AS, Winkler A. Clinical use of the activated partial thromboplastin time and prothrombin time for screening: a review of the literature and current guidelines for testing. Clin Lab Med. 2014 Sep;34(3):453-77. doi: 10.1016/j.cll.2014.06.005
•  Kitchen S, Jennings I, Woods TA, Preston FE. Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage. J Clin Pathol. 1996 Jan;49(1):10-4. doi: 10.1136/jcp.49.1.10.
• Gosselin RC, King JH, Janatpour KA, Dager WE, Larkin EC, Owings JT. Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing. Ann Pharmacother. 2004 Sep;38(9):1383-8. doi: 10.1345/aph.1D565.
• Gouin-Thibaut I, Martin-Toutain I, Peynaud-Debayle E, et al. Monitoring unfractionated heparin with APTT: a French collaborative study comparing sensitivity to heparin of 15 APTT reagents. Thrombosis Research. 2012 May;129(5):666-667. DOI: 10.1016/j.thromres.2011.11.016.
• Triplett DA. Screening for the lupus anticoagulant. Ricerca in Clinica E in Laboratorio. 1989; 19-379-89
• Denis-Magdelaine A et al; Sensitivity of sixteen APTT reagents for the presence of anticoagulant. Haemostasis 1995; 25:98-105/
• Rozen L, Copette F, Noubouossie DF, Demulder A. Evaluation of three APTT reagents in a routine laboratory: toward a compromise. Clin Lab. 2013;59(7-8):921-4. doi: 10.7754/clin.lab.2012.120909
• van Rossum, A.P., Vlasveld, L.T., van den Hoven, L.J.M., de Wit, C.W.M. and Castel, A. (2012), False prolongation of the activated partial thromboplastin time (aPTT) in inflammatory patients: interference of C‐reactive protein. Br J Haematol, 157: 394-395. https://doi.org/10.1111/j.1365-2141.2011.08990.x
• Gu, J.‐M., Ramsey, P., Evans, V., Tang, L., Apeler, H., Leong, L., Murphy, J.E., Laux, V. and Myles, T. (2014), Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94‐9027) for haemophilia A. Haemophilia, 20: 593-600. https://doi.org/10.1111/hae.12374
•  Hillarp A, Bowyer A, Ezban M, Persson P, Kitchen S. Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study. Haemophilia. 2017 May;23(3):458-465. doi: 10.1111/hae.13168.
• Ezban M, Hansen M, Kjalke M. An overview of turoctocog alfa pegol (N8-GP; ESPEROCT® ) assay performance: Implications for postadministration monitoring. Haemophilia. 2020;26(1):156-163. doi:10.1111/hae.13897
•  POUPLARD, Claire, JEANPIERRE, Emmanuelle, LASNE, Dominique, et al. Dosage de l’activité du facteur IX chez les patients hémophiles B substitués. In : Annales de Biologie Clinique. 2019. p. 41-52.
•  LASNE, Dominique, POUPLARD, Claire, NOUGIER, Christophe, et al. Dosage de l’activité du facteur VIII chez les patients hémophiles A substitués. Ann Biol Clin, 2019, vol. 77, no 1, p. 53-65.
•  

Podcasts associés :  

• Ask Stago S1E7- Suivi des HNF : TCA ou Anti-Xa ?

https://www.youtube.com/watch?v=-gAX8kA924I

• Ask Stago S2E3 - Le bilan biologique pour le diagnostic du lupus anticoagulant : 

https://www.youtube.com/watch?v=wHo-K8AwG8Y